|

Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

RECRUITINGN/ASponsored by University of Wisconsin, Madison
Actively Recruiting
PhaseN/A
SponsorUniversity of Wisconsin, Madison
Started2026-10-01
Est. completion2030-05
Eligibility
Age22 Years+
Healthy vol.Accepted
Locations1 site

Summary

This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.

Eligibility

Age: 22 Years+Healthy volunteers accepted
Clinics Inclusion Criteria:

* Clinic must be from a health system with at least two clinics that meet eligibility criteria and will agree to join.
* Number of unique patients with diabetes should be \>550 over any continuous 15-month period prior to the clinic providing a letter of support to participate in the trial.
* No point-of-care screening system in use for DR.
* Have an electronic health record to track patient data and agree to share limited data set as requested.
* Have a member of the clinical team who can commit to serving as the clinic champion for this study.
* Have the IT infrastructure to deploy an artificial-intelligence-based eye camera in the clinic.

Patient Inclusion Criteria:

* Diagnosis of type 1 or 2 diabetes
* No known diabetic retinopathy
* No diabetic retinopathy screening in the past 12 months

Patient Exclusion Criteria:

* Have a documented DR screening in the electronic health record within 12 months of the date of the primary care visit
* Contraindication includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion
* Pregnant

Conditions3

DiabetesDiabetes MellitusDiabetic Retinopathy

Locations1 site

UW School of Medicine and Public Health
Madison, Wisconsin, 53792

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.